1. Search Result
Search Result
Results for "

Gram-positive drug-resistant bacteria

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

2

Biochemical Assay Reagents

4

Peptides

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W984782

    GLUT Bacterial Fungal AMPK PPAR Reactive Oxygen Species (ROS) Apoptosis SOD Infection Metabolic Disease Cancer
    Flindersine is an alkaloid with multiple activities including antibacterial, antifungal, antitumor, and antidiabetic properties. Flindersine increases the activity of antioxidant enzymes, restores the levels of renal biomarkers, and reduces blood glucose, blood lipid, and insulin levels in diabetic rats. Flindersine inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, drug-resistant bacteria, as well as dermatophytes, filamentous fungi, and yeasts. Flindersine reduces the viability of cancer cells and induces apoptosis. Flindersine can be used in research related to breast cancer, type 2 diabetes, bacterial infections, and fungal infections .
    Flindersine
  • HY-103249

    Reutericycline

    Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-N14107

    Bacterial Endogenous Metabolite Infection
    Cinnabarin is a natural phenoxazinone red pigment derived from Pycnoporus sanguineus. Cinnabarin reduces rabies virus infection levels in neuroblastoma cells and causes cytopathic effects on neuroblastoma cell monolayers at high concentrations. Cinnabarin exhibits antibacterial activity against bacteria, with a preference for Gram-positive bacteria and human isolates. Cinnabarin can be used in studies related to rabies and drug-resistant Gram-positive bacteria .
    Cinnabarin
  • HY-178504

    Bacterial Infection
    Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .
    Lug-15
  • HY-105048A

    Bacterial Infection
    Omiganan pentahydrochloride is a cationic peptide compound with a broad antibacterial profile. Omiganan pentahydrochloride is capable of inhibiting a variety of bacteria, including yeast, and is active against both gram-positive and gram-negative bacteria. Omiganan pentahydrochloride is able to interact with the bacterial cell membrane, causing the destruction of the cell membrane and the death of the bacteria. Omiganan pentahydrochloride can be used for the study of antimicrobial activity against pathogens commonly associated with catheter-associated infections, including strains with drug-resistant phenotypes .
    Omiganan pentahydrochloride
  • HY-146811

    Bacterial Inflammation/Immunology
    HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .
    HSGN-94
  • HY-19234

    Antibiotic Bacterial Penicillin-binding protein (PBP) Beta-lactamase Infection
    FK-041 is an orally active cephalosporin antibiotic with high affinity for penicillin-binding proteins (PBPs). FK-041 exhibits broad-spectrum antibacterial activity, exerting potent antibacterial effects against Gram-positive bacteria, most Gram-negative bacteria, anaerobes, and so on. FK-041 also shows good efficacy against some drug-resistant strains such as penicillin-resistant Streptococcus pneumoniae. FK-041 is an antibacterial agent and can be used in the research of infectious diseases .
    FK-041
  • HY-N15059

    Bacterial Infection
    Cissetin shows activity against Gram-positive bacteria, including drug-resistant strains .
    Cissetin
  • HY-178952

    Bacterial Infection
    Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidease (SPase I), with an IC50 of 4.475 μM and a Kd of 16.3 μM. Anti-infective agent 12 has the ability to disrupt bacterial membranes and remove biofilms. Anti-infective agent 12 exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus suis, respectively. Anti-infective agent 12 remains effective against multi-drug resistant strains, but has weaker activity against Gram-negative bacteria (such as Escherichia coli and Salmonella), with MIC values > 64 μg/mL. Anti-infective agent 12 has low hemolytic activity and shows significant efficacy in mouse skin infection models .
    Anti-infective agent 12
  • HY-143326

    Bacterial Infection
    Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .
    Antibacterial agent 83
  • HY-N14520

    Bacterial Infection
    Pacidamycin 4N is a Pacidamycin antibiotic. Pacidamycin 4N has the activity against Pseudomonas aeruginosa with MIC of 4-16 μg/mL. it has no effect on other Gram-negative bacteria and Gram-positive bacteria, and no effect on drug-resistant pseudomonas aeruginosa .
    Pacidamycin 4N
  • HY-146595

    Bacterial Infection
    FtsZ-IN-1 is a potent FtsZ inhibitor with quinolinium ring. FtsZ-IN-1 has stronger antibacterial activity against Gram-positive bacteria with MICs of 0.5-8 μg/mL. FtsZ-IN-1 significantly causes cell elongation of B. subtilis by enhancing FtsZ polymerization. FtsZ-IN-1 exhibits low hemolytic toxicity and low tendency to induce agent resistance. FtsZ-IN-1 has against drug-resistant bacteria activity .
    FtsZ-IN-1
  • HY-P10540

    Bacterial Infection
    Pantinin-2 is a cysteine-free toxic peptide found in the emperor scorpion (paninus imperator). Pantinin-2 has high activity against Gram-positive bacteria but weak activity against Gram-negative bacteria. Pantinin-2 also exhibits activity against Candida tropicalis and has relatively mild hemolytic activity against human erythrocytes. Pantinin-2 can be used in the development of antimicrobial drugs for drug-resistant pathogens .
    Pantinin-2
  • HY-W353258R

    BAY 12-8039 monohydrate (Standard)

    Reference Standards Antibiotic Topoisomerase Bacterial Infection
    Moxifloxacin hydrochloride (BAY 12-8039) monohydrate (Standard) is the analytical standard of Moxifloxacin hydrochloride monohydrate. This product is intended for research and analytical applications. Moxifloxacin hydrochloride monohydrate is a blood-brain barrier-permeable, orally active topoisomerase II/IV inhibitor and a fluoroquinolone antibiotic. Moxifloxacin hydrochloride monohydrate disrupts bacterial DNA replication, transcription, repair and chromosome segregation processes. Moxifloxacin hydrochloride monohydrate exhibits activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, atypical pathogens, drug-resistant respiratory pathogens, Mycobacterium tuberculosis, mycoplasmas and Ureaplasma urealyticum.
    Moxifloxacin hydrochloride monohydrate (Standard)
  • HY-P3349

    Bacterial Infection
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] (Compound 9C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 25 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]
  • HY-P3348

    Bacterial Infection
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] (Compound 8C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 12.5 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]
  • HY-124195

    Bacterial Infection
    Antitubercular agent-57 is a selective antimycobacterial agent with low in vitro toxicity against mammalian cell lines including hepatocyte cell lines. Antitubercular agent-57 exhibits activity against drug-sensitive, multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains, and shows no cross-resistance with first-line or second-line antitubercular agents. Antitubercular agent-57 has no activity against Gram-positive bacteria, Gram-negative bacteria and fungal strains. Antitubercular agent-57 can be used in the research of tuberculosis and multidrug-resistant tuberculosis .
    Antitubercular agent-57
  • HY-W780694

    Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase Infection
    PD 124816 is an orally active fluoroquinolone antibiotic. PD 124816 exerts broad-spectrum antibacterial effects by inhibiting DNA gyrase (topoisomerase IV), and it has no cross-resistance with commonly used antibiotics. PD 124816 is effective against both Gram-positive and Gram-negative bacteria (MIC₉₀ ≤ 0.06 μg/mL), and the MIC₉₀ for anaerobic bacteria (Peptostreptococcus fragi) is 1 μg/mL. PD 124816 exhibits complete bactericidal activity in a mouse model of Mycobacterium leprae infection. PD 124816 can be used for studying mixed infections and infections caused by drug-resistant bacteria .
    PD 124816
  • HY-69174

    Bacterial
    1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.
    1-Amino-2,5-anhydro-1-deoxy-D-mannitol
  • HY-180151

    Lactate Dehydrogenase Bacterial DNA/RNA Synthesis Reactive Oxygen Species (ROS) Infection
    Antibacterial agent 306 (Compound 8c), a lactate dehydrogenase inhibitor, is a highly effective antibacterial agent, especially effective against Gram-positive bacteria. Antibacterial agent 306 exhibits MIC against Staphylococcus aureus of as low as 1 μg/mL. Antibacterial agent 306 can not only damage membrane integrity and block the replication of DNA by intercalation, but also make reactive oxygen species (ROS) burst. Antibacterial agent 306 can be used for research on anti-multi-drug resistant bacteria .
    Antibacterial agent 306
  • HY-179637

    Bacterial DNA/RNA Synthesis Infection
    RNAP-σ interaction-IN-4 (Compound 3a) is an inhibitor of the RNA polymerase-sigma factor interaction (RNAP-σ) with MIC values against S. pneumoniae and S. aureus of 1 μg/mL and 2 μg/mL, respectively. RNAP-σ interaction-IN-4 exhibits strong bactericidal properties by interfering with the interaction of β′CH−σ and disrupting the transcription of bacteria. RNAP-IN-2 shows significant efficacy in sepsis models. RNAP-σ interaction-IN-4 can be used to study Gram-positive bacterial infections caused by multi-drug resistant strains .
    RNAP-σ interaction-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: